Primary Myelofibrosis
"Primary Myelofibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
Descriptor ID |
D055728
|
MeSH Number(s) |
C15.378.190.636.765
|
Concept/Terms |
Primary Myelofibrosis- Primary Myelofibrosis
- Myelofibroses, Primary
- Myelofibrosis, Primary
- Primary Myelofibroses
- Bone Marrow Fibrosis
- Bone Marrow Fibroses
- Fibroses, Bone Marrow
- Fibrosis, Bone Marrow
- Myelofibrosis
- Myelofibroses
- Idiopathic Myelofibrosis
- Myeloid Metaplasia
- Metaplasia, Myeloid
- Metaplasias, Myeloid
- Myeloid Metaplasias
- Myelosclerosis
- Myeloscleroses
- Myelosis, Nonleukemic
- Myeloses, Nonleukemic
- Nonleukemic Myeloses
- Nonleukemic Myelosis
- Chronic Idiopathic Myelofibrosis
- Agnogenic Myeloid Metaplasia
- Agnogenic Myeloid Metaplasias
- Metaplasia, Agnogenic Myeloid
- Metaplasias, Agnogenic Myeloid
- Myeloid Metaplasia, Agnogenic
- Myeloid Metaplasias, Agnogenic
- Myelofibrosis With Myeloid Metaplasia
|
Below are MeSH descriptors whose meaning is more general than "Primary Myelofibrosis".
Below are MeSH descriptors whose meaning is more specific than "Primary Myelofibrosis".
This graph shows the total number of publications written about "Primary Myelofibrosis" by people in this website by year, and whether "Primary Myelofibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2013 | 1 | 1 | 2 | 2014 | 1 | 0 | 1 | 2015 | 2 | 0 | 2 | 2016 | 1 | 0 | 1 | 2020 | 1 | 0 | 1 | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Primary Myelofibrosis" by people in Profiles.
-
Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 09; 20(9):1033-1062.
-
Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biol Blood Marrow Transplant. 2020 05; 26(5):893-901.
-
Gangat N, Marinaccio C, Swords R, Watts JM, Gurbuxani S, Rademaker A, Fought AJ, Frankfurt O, Altman JK, Wen QJ, Farnoud N, Famulare CA, Patel A, Tapia R, Vallapureddy RR, Barath S, Graf A, Handlogten A, Zblewski D, Patnaik MM, Al-Kali A, Dinh YT, Englund Prahl K, Patel S, Nobrega JC, Tejera D, Thomassen A, Gao J, Ji P, Rampal RK, Giles FJ, Tefferi A, Stein B, Crispino JD. Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. Clin Cancer Res. 2019 Aug 15; 25(16):4898-4906.
-
Soderquist CR, Ewalt MD, Czuchlewski DR, Geyer JT, Rogers HJ, Hsi ED, Wang SA, Bueso-Ramos CE, Orazi A, Arber DA, Hexner EO, Babushok DV, Bagg A. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol. 2018 05; 31(5):690-704.
-
Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 12; 14(12):1572-1611.
-
Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E, Scandura J, Wang H, Zhou XK, Silver RT, van Besien K. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016 May; 16(5):297-303.
-
Rajasekaran A, Ngo TT, Abdelrahim M, Glass W, Podoll A, Verstovsek S, Abudayyeh A. Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib. BMC Nephrol. 2015 Aug 01; 16:121.
-
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw. 2015 Apr; 13(4):424-34.
-
Mayer JE, Schiano TD, Fiel MI, Hoffman R, Mascarenhas JO. An association of myeloproliferative neoplasms and obliterative portal venopathy. Dig Dis Sci. 2014 Jul; 59(7):1638-41.
-
Schepers K, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, Wagers AJ, Hsiao EC, Passegu? E. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell. 2013 Sep 05; 13(3):285-99.
|
People ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|